Small-Cap Surge: Countdown to Key Catalysts (ORKT, GWAV, CGTX, ZNTL, PBM)

1/26/20258 min read

Mastering the unpredictable world of penny stocks calls for keen insight into upcoming catalysts and pivotal levels that could shape their trajectory. In this article, we break down the intricacies of five high-risk, high-reward penny stocks, spotlighting the critical catalysts and essential levels that smart investors should keep on their radar.

Orangekloud Technology Inc. (NASDAQ: ORKT) - Orangekloud Technology Inc. saw its shares rise nearly 3% last week, closing at $0.69. In October, the company introduced its AI-powered no-code application development platform at GITEX Global, one of the world's most prominent tech exhibitions. Orangekloud's founder and CEO, Alex Goh, expressed enthusiasm about the platform, stating, "We are thrilled to have completed the development of this groundbreaking AI-powered no-code platform and to have showcased it at GITEX. We believe it left a strong impression on industry leaders and potential partners, and we anticipate these connections will drive significant revenue growth and open opportunities in new regions and industries." This month, Orangekloud announced the Beta launch of its new platform, eMOBIQ® AI, set for February 3, 2025. The company described this launch as a game-changer, redefining application development and solidifying its position at the forefront of global digital transformation. eMOBIQ AI uses advanced AI agents and proprietary orchestration techniques to automate key stages of development, including capturing requirements, generating UI wireframes, and building applications. This approach streamlines workflows, drastically reduces development time, and ensures high precision and quality. Alex Goh highlighted the platform's transformative potential, saying, "We are proud to empower developers, businesses, and individuals to effortlessly turn ideas into real applications using natural language. eMOBIQ AI simplifies the entire development process, making it faster and more accessible than ever. This represents a major leap forward in accelerating innovation and simplifying software creation across industries." We will be monitoring for increased trading volume and a potential breakout above the $0.73–$0.74 resistance level as we await further updates from the company.

--

Greenwave Technology Solutions Inc. (NASDAQ: GWAV) - Greenwave Technology Solutions Inc. shares ended last week down 3%, closing at $0.42. At the end of December, the company released revenue guidance of $43–$45 million for fiscal year 2025. Sims Metal Management, one of Greenwave's key customers, contributes approximately $20 million annually in scrap metal purchases. The company is also involved in Hurricane Helene recovery efforts through a contract with Core Tree Care, valued at $15–$35 million, which runs through March 2026. This contract is tied to a prime agreement awarded by the U.S. Army Corps of Engineers. In the broader market, Greenwave is positioned to benefit from a shift in the steel industry, where U.S. producers are targeting 97% recycled material to meet an additional 16 million tons of capacity. Rising demand for high-quality recycled metal and industry consolidation are creating favorable conditions for growth. Greenwave’s domestic sales are projected to increase from 41% to 75% by 2025, driven by anticipated tariffs and trade policies. This shift is expected to reduce transportation costs significantly, improving margins and boosting free cash flow. Furthermore, Greenwave’s portfolio of exclusive operational licenses, many protected by grandfathered municipal codes, creates substantial barriers to entry in its tightly regulated markets. The company is well-positioned to capitalize on regional infrastructure investment, rising domestic demand for recycled metal, and industry consolidation. Backed by over $30 million in advanced equipment, Greenwave is strategically set to grow revenues and enhance shareholder value in fiscal year 2025. This month, Greenwave announced a securities purchase agreement with institutional and accredited investors, raising approximately $4 million in gross proceeds through a registered direct offering and concurrent private placement. The agreement includes the sale of 7,544,323 shares of common stock at $0.5302 per share, along with warrants to purchase an equal number of shares at the same price. The warrants will be exercisable upon stockholder approval and will expire five years after approval. The offering, originally expected to close on January 14, 2025, has not yet closed. Additionally, Greenwave secured an exclusive contract with the City of Virginia Beach, the largest city in Virginia and a key industrial hub. Under this agreement, the company becomes the city’s sole provider of scrap metal recycling services, further solidifying its market presence and reputation as a trusted leader in the industry. As we await further updates, we will be watching for increased trading volume and a potential breakout above the $0.45 resistance level.

--

Cognition Therapeutics, Inc. (NASDAQ: CGTX) - Cognition Therapeutics, Inc. shares ended last week down 4%, closing at $0.75. In December, the company announced topline results from the exploratory Phase 2 SHIMMER study, which showed that CT1812 produced significant therapeutic responses in patients with dementia with Lewy bodies (DLB) across behavioral, functional, cognitive, and movement measures. "The results from this exploratory Phase 2 trial demonstrated that CT1812 could have a meaningful, positive impact on DLB patients across multiple aspects of their condition," said Dr. James E. Galvin, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and a principal investigator in the SHIMMER study. "DLB is a multifactorial disease where patients experience a wide range of symptoms, and these results suggest CT1812 holds great promise for both patients and their caregivers. The SHIMMER topline results are exciting and very promising, and I look forward to collaborating with Cognition as they determine the next steps for CT1812." The study also showed a marked reduction in caregiver distress, indicating a meaningful improvement in the daily lives of those receiving the treatment. Patients treated with CT1812 experienced a significant slowing of decline across three cognitive measures compared to placebo, including a 91% reduction in fluctuations in attention. Detailed data from the study will be presented at the International Lewy Body Dementia Conference (ILBDC) from January 29–31, 2025. "These topline results exceeded our expectations and further support the broad potential of CT1812 across neurodegenerative disorders," said Anthony Caggiano, M.D., Ph.D., Cognition's chief medical officer and head of R&D. "We will continue analyzing CT1812's activity in DLB as more data become available and look forward to presenting these findings at upcoming medical conferences and discussing them with the FDA at an end-of-Phase 2 meeting." As we await additional updates from the company, we will be watching for increased trading volume and a potential breakout above the $0.79 resistance level.

--

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) - Zentalis Pharmaceuticals, Inc. shares closed last week down 3%, ending at $2.22. Earlier this month, the company announced that the FDA granted Fast Track Designation to azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (PROC) who test positive for Cyclin E1 protein levels through immunohistochemistry. The Fast Track Designation aims to facilitate the development and expedite the review of investigational medicines that have the potential to treat serious conditions and address unmet medical needs. "Zentalis is fully committed to advancing azenosertib for patients with gynecological malignancies," stated Ingmar Bruns, the company’s Chief Medical Officer. "The FDA's decision to grant Fast Track Designation underscores the significant unmet medical need among Cyclin E1-positive ovarian cancer patients, a population often associated with chemotherapy resistance and poor outcomes. This designation offers valuable benefits, including the potential to accelerate regulatory review. We look forward to sharing updated clinical data for azenosertib and providing a regulatory update, including plans for registration-intent studies, during our corporate event on January 29." Mark Lackner, Chief Scientific Officer, emphasized the strong scientific foundation behind azenosertib, stating, "Preclinical models with high levels of Cyclin E1 activation have shown a heightened sensitivity to azenosertib inhibition. These findings, supported by clinical data from selected patients in our studies, validate a biomarker-driven approach to identify those most likely to benefit from this treatment." On January 29, 2025, at 8:00 AM ET, Zentalis plans to host a webcast to present updated findings and provide a regulatory and development overview for azenosertib. The webcast will include topline results from 102 patients enrolled in Part 1b of the Phase 2 DENALI study of azenosertib monotherapy in platinum-resistant high-grade serous ovarian cancer, as well as final results from patients treated with therapeutic doses in the Phase 1b azenosertib monotherapy trial involving solid tumors, including 69 PROC patients. The company will also share data from the Phase 1/2 MAMMOTH trial, which evaluated azenosertib both as a monotherapy and in combination with the PARP inhibitor niraparib in PARP-resistant PROC in partnership with GSK. In addition, Zentalis will present the design of its registration-intent study, provide a regulatory update, and release initial data from the Phase 1 study of azenosertib combined with the BEACON regimen (encorafenib and cetuximab) in BRAF-mutant metastatic colorectal cancer, conducted in collaboration with Pfizer. As we await further updates from the company, we will be monitoring for increased trading volume, support holding at $2.15, and a potential resistance breakout at $2.35. As the saying goes, "You’ve got to know when to hold ’em, know when to fold ’em, know when to walk away."

--

Psyence Biomedical Ltd. (NASDAQ: PBM) - Psyence Biomedical Ltd. shares closed last week with a 6% gain, ending at $1.82. In December, the company highlighted significant progress in its ongoing Phase IIb clinical trial evaluating naturally derived psilocybin, combined with psychotherapy, as a potential treatment for Adjustment Disorder in palliative care patients with life-limiting cancer diagnoses. Two trial sites in Australia—Vitalis and EMPAX—have been activated, and patient screening is underway. Psyence Biomed expects the first patients to be randomized into the study in January, with therapist training actively continuing at both sites. The company is also considering additional sites to expand trial participation. Dr. Clive Ward-Able, Medical Director of Psyence Biomed, stated, "In collaboration with iNGENū and ACTioN, we have made substantial progress in advancing start-up activities for our Phase IIb trial and are prepared to commence patient randomization and treatment shortly after the holiday season. With support from the ACTioN team and their strong patient and provider outreach capabilities, we anticipate smooth recruitment progress. We look forward to sharing topline results from this trial in the second half of 2025." Last month, Psyence Biomed announced the closing of its previously disclosed private placement, which involved the sale of 1,000,000 common shares (or pre-funded warrants), along with Series A and Series B common warrants to purchase up to an additional 2,000,000 shares. The purchase price was set at $2.00 per common share. Additionally, the company recently filed an F-1 registration statement, which has yet to take effect. As we await further updates, we will be monitoring for increased trading volume and a potential resistance breakout at $1.90.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.